RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $141
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Lisa Walter maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform and raises the price target from $137 to $141.
RBC Capital analyst Lisa Walter maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform and raises the price target from $137 to $141.